Clinical Trials in third countries: EU plans ethics review at marketing authorisation phase
This article was originally published in SRA
Vibha Sharma reports from a European Medicines Agency workshop on the monitoring of ethics and GCP considerations when conducting clinical trials in third countries.
You may also be interested in...
Reports from Norway about deaths in very frail, elderly patients soon after receiving Pfizer/BioNTech’s COVID-19 jab have drawn regulatory scrutiny. While the European Medicines Agency has launched an investigation, Australia is examining the need for specific warnings about risks of vaccination in the very frail elderly or terminally ill patients.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.